Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclopropane SCHEMBL27363746 | 0.94 | LMNA (0.47) | LMNAALDH1A1TSHRMAPTHTT | |
| SCHEMBL26199851 | 0.87 | LMNA (0.46) | LMNAALDH1A1TSHRMAPTHTT | |
| SCHEMBL72471 | 0.82 | LMNA (0.62) | LMNAALDH1A1TSHRMAPTHTT | |
| SCHEMBL13502946 | 0.81 | ALDH1A1 (0.40) | LMNAALDH1A1TSHREPHX2 | |
| SCHEMBL6651373 | 0.81 | TSHR (0.55) | LMNAALDH1A1TSHRMAPTHTT | |
| SCHEMBL498581 | 0.81 | LMNA (0.52) | LMNAALDH1A1TSHRMAPTHTT | |
| SCHEMBL17908830 | 0.80 | LMNA (0.52) | LMNAALDH1A1TSHRMAPTHTT | |
| SCHEMBL17909443 | 0.80 | LMNA (0.52) | LMNAALDH1A1TSHRMAPTHTT | |
| SCHEMBL31402602 | 0.79 | LMNA (0.60) | LMNAALDH1A1TSHRMAPTHTT | |
| SCHEMBL3897660 | 0.79 | LMNA (0.50) | LMNAALDH1A1TSHRMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109796339-A | A kind of preparation method of 3- (2- ethylpropoxy) propionic acid -2- ethylpropyl | 韶关市合众化工有限公司 | 2019-05-24 | — | — | CN | claimed |
| CN-109651147-A | A kind of preparation method of 3- isopropoxy isopropyl propionate | 韶关市合众化工有限公司 | 2019-04-19 | — | — | CN | claimed |
| US-6415614-B1 | CONTROLLING VAPOR PRESSURE OF MIXTURE | VISTEON GLOBAL TECHNOLOGIES, INC. | 2002-07-09 | — | — | US | claimed |
| US-20240239828-A1 | MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240072809-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | UNIV YALE (US) | 2023-07-27 | — | — | US | disclosed |
| CN-109651147-A | A kind of preparation method of 3- isopropoxy isopropyl propionate | 韶关市合众化工有限公司 | 2019-04-19 | — | — | CN | disclosed |
| CN-109651147-A | A kind of preparation method of 3- isopropoxy isopropyl propionate | 韶关市合众化工有限公司 | 2019-04-19 | — | — | CN | disclosed |
| CN-109651147-A | A kind of preparation method of 3- isopropoxy isopropyl propionate | 韶关市合众化工有限公司 | 2019-04-19 | — | — | CN | disclosed |
| CN-104203905-A | Process for producing beta-alkoxypropionamide | IDEMITSU KOSAN CO | 2014-12-10 | — | — | CN | disclosed |
| US-20140193510-A1 | Polymer-Agent Conjugates, Particles, Compositions, and Related Methods of Use | CERULEAN PHARMA INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-4978754-A | REACTING B-ALKOXY-SUBSTITUTED CARBOXYLATE WITH CYCLIC AMINE, REMOVING ALCOHOL IN PRESENCE OF BASIC CATALYST | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1990-12-18 | — | — | US | disclosed |
| EP-0321256-A2 | Process of preparing unsaturated carboxylic acid amides | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1989-06-21 | — | — | EP | disclosed |
| US-4835175-A | Indole derivatives pharmaceutical preparations based thereon, and β-receptor stimulation therewith | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-05-30 | — | — | US | disclosed |
| US-3987089-A | PLATINUM GROUP METAL SALT CATALYST, REOXIDIZING AGENT | ROHM AND HAAS COMPANY (US) | 1976-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | ASGR1, ENGASE, FCGR2A | LMNA 2955/4885ALDH1A1 3319/4885TSHR 645/4885 |
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | ASGR1, LDLR, FCGR2A | LMNA 3307/4885ALDH1A1 3256/4885TSHR 665/4885 |
| US-20240239828-A1 | MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | M6PR, ASGR1, IGF2R | LMNA 2973/4885ALDH1A1 4019/4885TSHR 560/4885 |
| US-20140193510-A1 | Polymer-Agent Conjugates, Particles, Compositions, and Related Methods of Use | LPXN, POLI, BRCA1 | LMNA 461/4885ALDH1A1 1992/4885TSHR 3588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.